1/23/2025

Janusmed kön och genus

Janusmed kön och genus – Raltegravir

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Raltegravir

Raltegravir

Klass : A

Produkter

ISENTRESS

ISENTRESS
ATC-koder

J05AJ01

J05AJ01
Substanser

raltegravir, raltegravirkalium

raltegravir, raltegravirkalium
Sammanfattning

Inga skillnader mellan män och kvinnor har rapporterats avseende farmakokinetiska parametrar eller effekt av raltegravir. Mindre observationella studier visar på mer gastrointestinala biverkningar hos kvinnor och mer muskelbesvär och kreatininkinasstegring hos män.

Inga skillnader mellan män och kvinnor har rapporterats avseende farmakokinetiska parametrar eller effekt av raltegravir. Mindre observationella studier visar på mer gastrointestinala biverkningar hos kvinnor och mer muskelbesvär och kreatininkinasstegring hos män.
Background

Antiretrovirals for treatment of HIV are always given as a combination of at least three medicines. Cobicistat is used to boost the effect of other antiretroviral drugs. As studies on HIV patients always include patients receiving combination therapy it is difficult to know which of the studied medicines that cause changes in effect and/or adverse events.

Pharmacokinetics and dosing
The producer reports no differences between men and women in pharmacokinetic variables and does not recommend differences in dosing according to patient’s sex [1]. In a multicenter, open-label one arm study of raltegravir in HIV patients (109 men, 97 women) pharmacokinetic variables were similar in men and women [2].

Effects
No sex differences were found in an Italian observational cohort study of determinants of virological failure in triple-class experienced patients receiving raltegravir-based regimens (69 men, 32 women) [3]. Similarly, in a multicenter, open-label one arm study of raltegravir in HIV patients (109 men, 97 women) virologic response was found to be similar in men and women [2].
# Adv......

Antiretrovirals for treatment of HIV are always given as a combination of at least three medicines. Cobicistat is used to boost the effect of other antiretroviral drugs. As studies on HIV patients always include patients receiving combination therapy it is difficult to know which of the studied medicines that cause changes in effect and/or adverse events. # Pharmacokinetics and dosing The producer reports no differences between men and women in pharmacokinetic variables and does not recommend differences in dosing according to patient’s sex [1]. In a multicenter, open-label one arm study of raltegravir in HIV patients (109 men, 97 women) pharmacokinetic variables were similar in men and women [2]. # Effects No sex differences were found in an Italian observational cohort study of determinants of virological failure in triple-class experienced patients receiving raltegravir-based regimens (69 men, 32 women) [3]. Similarly, in a multicenter, open-label one arm study of raltegravir in HIV patients (109 men, 97 women) virologic response was found to be similar in men and women [2]. # Adverse effects In the multicenter study of raltegravir in HIV patients mentioned above (109 men, 97 women) drug-related clinical adverse events were more common in women compared to men (18% women, 8% men) and more common in black women compared to non-black women. The difference between men and women was largely attributable to various gastrointestinal adverse events which were more common in women (10% vs 6% in men) [2]. The risk of muscular symptoms and creatinine phosphokinase (CPK) elevation as an adverse effect of raltegravir was studied in a prospective multicenter observational study (333 men, 163 women) of whom 21% had CPK increase. Women had a lower risk of CPK increase than men [4]. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan). # Other information In a multicenter, open-label one arm study of raltegravir in HIV patients (109 men, 97 women) the discontinuation rate was higher in women (18% vs 13% in men) [2]. A review has described drug exposure in the genital tract of men and women which is of interest in viral transferal and in effect of pre-exposure prophylactic treatment. In men, concentrations in seminal fluid were described to be highest for nucleoside analogues and lowest for protease inhibitors and efavirenz. Seminal accumulation of raltegravir and maraviroc was defined as moderate. The rank order of accumulation presented in the review is nucleoside/nucleotide reverse transcriptase inhibitors [lamivudine/zidovudine/tenofovir/didanosine > stavudine/abacavir] > raltegravir > indinavir/maraviroc/nevirapine >> efavirenz/protease inhibitors [amprenavir/atazanavir/darunavir > lopinavir/ritonavir > saquinavir] > enfuvirtide. In the female genital tract, the nucleoside analogues also were described as having high accumulation ratios, whereas protease inhibitors have limited penetration; however, substantial variability exists. Second generation non-nucleoside reverse transcriptase inhibitor etravirine, and maraviroc and raltegravir, have been found to demonstrate effective accumulation in cervicovaginal secretions. The rank of accumulation presented in the review is nucleoside/nucleotide reverse transcriptase inhibitor [zidovudine/lamivudine/didanosine > emtricitabine/tenofovir] > indinavir > maraviroc/raltegravir/darunavir/etravirine > nevirapine/abacavir > protease inhibitors [amprenavir/atazanavir/ritonavir] > lopinavir/stavudine/efavirenz > saquinavir [5].
Försäljning på recept

Fler män än kvinnor hämtade ut läkemedel innehållande raltegravir (ATC-kod J05AX08) på recept i Sverige år 2017, totalt 303 män och 142 kvinnor [6].
Referenser
  1. Isentress (raltegravir). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.
  2. Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F et al. Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study. AIDS Res Hum Retroviruses. 2013;29(6):859-70.
  3. Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE et al. Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS. 2012;23(7):459-63.
  4. Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 2015;45(3):289-94.
  5. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]
Uppdaterat

Litteratursökningsdatum: 7/18/2018

Litteratursökningsdatum: 7/18/2018
Fasstexter